# Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients

> **NCT03084952** · PHASE2 · UNKNOWN · sponsor: **Infan Industria Quimica Farmaceutica Nacional** · enrollment: 52 (estimated)

## Conditions studied

- Leishmaniasis; American, Cutaneous
- Drug Side Effect

## Interventions

- **DRUG:** 18-Methoxycoronaridine
- **DRUG:** Glucantime

## Key facts

- **NCT ID:** NCT03084952
- **Lead sponsor:** Infan Industria Quimica Farmaceutica Nacional
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05
- **Primary completion:** 2023-12
- **Final completion:** 2024-07
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03084952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03084952, "Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03084952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*